SNYライブシグナル | Getagraph.comで利益を最大化

買う 416 min ago

@ $49.48

発行日: 26 4月 2024 @ 04:49

リターン: -0.24%

前回のシグナル: 4月 25 - 22:31

前回のシグナル: 売る

リターン: 1.46 %

Live Chart Being Loaded With Signals

Commentary (26 4月 2024 @ 05:00):
Our systems believe the stock currently is undervalued by 0.54% compare to its pairs and should correct upwards.

Sanofi, together with its subsidiaries, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally...

Stats
本日の出来高	6.47M
平均出来高	1.93M
時価総額	119.44B
EPS	$0 ( 2024-02-01 )
Last Dividend	$1.903 ( 2023-05-30 )
Next Dividend	$0 ( N/A )
P/E	21.55
ATR14	$1.137 (2.30%)

相関 (AI algo v.1.1b): Undervalued: 0.54% $49.59 paired level. (アルゴリズムは、最も相関の高い株式の変更をリアルタイムで追跡し、即時の更新を提供します)

ボリューム相関

長: -0.02 (neutral)

短: -0.98 (very strong negative)

Signal:(16) Possible Trading Opportunity Present (swing)

Sanofi American 相関

10 最も正の相関
PPH	0.936
PWOD	0.93
ACAHU	0.925
WLFC	0.914
NWFL	0.914
EVOP	0.913
ROST	0.91
SGHT	0.909
HZNP	0.907
MGI	0.907

10 最も負の相関
LNSR	-0.936
MEDS	-0.922
VS	-0.919
LHDX	-0.915
STRC	-0.912
TIL	-0.911
QLGN	-0.91
ULBI	-0.91
PLMR	-0.909
SG	-0.909

知っていましたか？

相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関（1つの変数が増加すると、もう一方は減少する）、1は完全な正の相関（1つの変数が増加すると、もう一方も増加する）、0は相関がないことを示します（変数間に関係がない）。

相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。

Sanofi American 相関 - 通貨/商品

-0.66
( moderate negative )

-0.85
( strong negative )

0.00
( neutral )

-0.12
( neutral )

0.09
( neutral )

0.44
( neutral )

Sanofi American 財務諸表

Annual	2023
収益:	$43.07B
総利益:	$26.50B (61.52 %)
EPS:	$4.31

Q4	2023
収益:	$22.88B
総利益:	$14.68B (64.16 %)
EPS:	$1.570

Q3	2023
収益:	$12.70B
総利益:	$8.86B (69.75 %)
EPS:	$2.01

Q2	2023
収益:	$10.68B
総利益:	$7.41B (69.41 %)
EPS:	$2.74

Financial Reports:

No articles found.

Sanofi American Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
$0 (N/A)	$0 (N/A)	$0 (N/A)	$3.28 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)

Sanofi American Dividend Information - Dividend Knight

Dividend Sustainability Score: 10.00 - good (100.00%) | Divividend Growth Potential Score: 7.30 - Increase likely (46.04%)

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information

First Dividend	$0.462	2003-05-28
Last Dividend	$1.903	2023-05-30
Next Dividend	$0	N/A
Payout Date	2023-06-23
Next Payout Date	N/A
# dividends	24	--
Total Paid Out	$33.25	--
Avg. Dividend % Per Year	3.34%	--
Score	4.99	--
Div. Sustainability Score	10.00
Div.Growth Potential Score	7.30
Div. Directional Score	9.72	--

Next Divdend (Est)
(2025-02-10)

$1.985 Estimate 3.15 %

Dividend Stability

0.25 Very Poor

Dividend Score

4.99

Pay Frequency

Annually

Yearly Payout

Year	Amount	Yield
2003	$0.462	1.49%
2004	$0.610	1.60%
2005	$0.799	2.01%
2006	$0.912	2.00%
2007	$1.145	2.48%
2008	$1.510	3.31%
2009	$1.419	4.34%
2010	$1.627	3.99%
2011	$1.822	5.55%
2012	$1.756	4.72%
2013	$1.862	3.89%
2014	$1.910	3.69%
2015	$1.618	3.55%
2016	$1.630	3.86%
2017	$1.577	3.84%
2018	$1.861	4.30%
2019	$1.739	4.06%
2020	$1.753	3.46%
2021	$1.906	3.91%
2022	$2.04	4.02%
2023	$3.28	6.69%
2024	$0	0.00%

Dividend Commentary

The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. Furthermore, its high Dividend Growth Potential Score (DGPS) signals potential dividend growth. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.

Top 10 dividend Companies for NASDAQ

Symbol	Title	Last dividend	Frequency	Years Dividend	Yearly Dividend	Score
OXLC	Dividend Royal	2023-12-14	Monthly	14	10.00%	8.50
PSEC	Dividend Royal	2023-12-26	Monthly	21	7.04%	8.50
SLVO	Dividend Royal	2023-11-20	Monthly	12	10.77%	8.50
QYLD	Dividend Royal	2023-11-20	Monthly	11	7.50%	8.50
OXSQ	Dividend Diamond	2023-12-14	Monthly	21	9.10%	8.50
GAIN	Dividend Royal	2023-12-04	Monthly	20	8.19%	8.50
GLDI	Dividend Royal	2023-11-20	Monthly	12	7.15%	8.50
HRZN	Dividend King	2023-12-18	Monthly	15	6.60%	8.45
USOI	Dividend Royal	2023-11-20	Monthly	8	16.70%	8.28
PFLT	Dividend King	2023-11-15	Monthly	14	6.50%	8.27

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	0.139	1.500	7.23	10.00	[0 - 0.5]
returnOnAssetsTTM	0.0627	1.200	7.91	9.49	[0 - 0.3]
returnOnEquityTTM	0.108	1.500	9.92	10.00	[0.1 - 1]
payoutRatioTTM	0.579	-1.000	4.21	-4.21	[0 - 1]
currentRatioTTM	1.267	0.800	8.66	6.93	[1 - 3]
quickRatioTTM	0.827	0.800	9.84	7.87	[0.8 - 2.5]
cashRatioTTM	0.360	1.500	9.11	10.00	[0.2 - 2]
debtRatioTTM	0.132	-1.500	7.80	-10.00	[0 - 0.6]
interestCoverageTTM	9.29	1.000	7.67	7.67	[3 - 30]
operatingCashFlowPerShareTTM	8.20	2.00	7.27	10.00	[0 - 30]
freeCashFlowPerShareTTM	5.60	2.00	7.20	10.00	[0 - 20]
debtEquityRatioTTM	0.225	-1.500	9.10	-10.00	[0 - 2.5]
grossProfitMarginTTM	0.678	1.000	2.03	2.03	[0.2 - 0.8]
operatingProfitMarginTTM	0.260	1.000	6.80	6.80	[0.1 - 0.6]
cashFlowToDebtRatioTTM	0.615	1.000	7.69	7.69	[0.2 - 2]
assetTurnoverTTM	0.452	0.800	-0.322	-0.258	[0.5 - 2]
Total Score				12.14

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	13.85	1.000	8.70	0	[1 - 100]
returnOnEquityTTM	0.108	2.50	9.95	10.00	[0.1 - 1.5]
freeCashFlowPerShareTTM	5.60	2.00	8.13	10.00	[0 - 30]
dividendYielPercentageTTM	4.06	1.500	10.00	0	[0 - 0.4]
operatingCashFlowPerShareTTM	8.20	2.00	7.27	10.00	[0 - 30]
payoutRatioTTM	0.579	1.500	4.21	-4.21	[0 - 1]
pegRatioTTM	0.632	1.500	9.12	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0.180	1.000	8.01	0	[0.1 - 0.5]
Total Score				7.30

Sanofi American

Sanofi, together with its subsidiaries, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through three segments: Pharmaceuticals, Vaccines, and Consumer Healthcare. The company provides specialty care products, including human monoclonal antibodies; products for multiple sclerosis, neurology, other inflammatory diseases, immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes; and cardiovascular and established prescription products. It also supplies poliomyelitis, pertussis, and hib pediatric vaccines; and influenza, adult booster, meningitis, and travel and endemic vaccines. In addition, the company offers allergy, cough and cold, pain, liver care, physical and mental wellness, probiotics, digestive, and nutritional products; and other products, such as daily body lotions, anti-itch products, moisturizing and soothing lotions, and body and foot creams, as well as powders for eczema. Further, it has various pharmaceutical products and vaccines in development stage. Sanofi has collaboration agreement with GlaxoSmithKline to develop a recombinant Covid-19 vaccine; and a research collaboration with Stanford University School of Medicine to advance the understanding of immunology and inflammation through open scientific exchange. It also has a collaboration and license option agreement with Prellis Biologics, Inc. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was founded in 1973 and is headquartered in Paris, France.